Innovative scientific approaches have facilitated significant progress in drug development during recent decades, offering amazing new treatment options to patients across a range of chronic diseases. However, safety and tolerability of drug candidates and newly approved drugs often remain a key concern, leading to labelling restrictions, black box warnings, and withdrawal of otherwise promising innovative medicines.
The TransBioLine project aims to develop novel safety biomarkers that will reliably indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes. By the end of the project, the team will have set up an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, providing to the scientific community, industry and patients with detailed data across a large spectrum of advanced safety biomarkers.
Latest News
2nd Consortium Meeting
TransBioLine Consortium met in Sitges, Barcelona, on the 30th September and 1st October 2019. Members of the 27 partners of the Consortium met in Sitges to report on progress during the first half year of the project life as well as to discuss on project specific topics as Patient recruitment, [...]
TransBioLine Kick off Meeting
From February 28th to March 1st 2019 participants from the 27 partners of the Consortium met during two full days to begin a new adventure. The meeting took place in Basel, Switzerland, in Novartis premises to lay the foundations of the new IMI2 TransBioLine Project. This is one of the [...]
TransBioLine Press Release
Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project […]
TransBioLine promises a decisive advance in biomarker discovery, development, validation, regulatory qualification and application, and bring about a fundamental change in the way drug safety is monitored in clinical trials, and toxicities are diagnosed and managed in clinical practice.